Daily Medication Pearl: Tildrakizumab-asmn (Ilumya)
Tildrakizumab-asmn (Ilumya) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Medication Pearl of the Day: Tildrakizumab-asmn (Ilumya)
Indication: Tildrakizumab-asmn (Ilumya) is an interleukin-23 antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Dosing: Injection 100 mg/mL solution in a single-dose prefilled syringe.
- Dosage forms: Recommended dose is 100 mg at weeks 0, 4, and every 12 weeks thereafter.
- Adverse events: Most common (≥1%) adverse reactions associated with tildrakizumab treatment are upper respiratory infections, injection site reactions, and diarrhea.
- Mechanism of action: Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.